| Literature DB >> 28134286 |
Yin Zongyi1, Li Baifeng1, Zou Funian1, Li Hao1, Wang Xin1.
Abstract
In this study, we determined the risk factors for acute kidney injury (AKI) following orthotopic liver transplantation (OLT) in China. We collected 5074 donation after cardiac death (DCD) OLT recipients who underwent surgery between January 1, 2010, and December 31, 2015, in 86 academic hospitals or transplant centers in China. Univariate and multivariate analyses were used to investigate the criticality of donor, graft, or recipient variables in the development of post-OLT AKI. In all, 4482 patients were included (median age, 49.31 years). Post-OLT AKI occurred in 3.97% patients, and 73.6% of all OLT patients were male. The 1- and 5-year cumulative survival rates (CSRs) of the AKI group were 33.95% and 25.24%, respectively, compared with 86.34% and 70.05%, respectively, of the non-AKI group (P < 0.001). The independent risk factors for post-OLT AKI were blood loss, cold ischemia time, warm ischemia time, preoperative serum creatinine, the treatment period with dopamine, overexposure to calcineurin inhibitor, and combined mycophenolate mofetil use (P < 0.05). These had a high prediction accuracy for post-OLT AKI (area under the curve [AUC] = 0.740).Entities:
Mesh:
Substances:
Year: 2017 PMID: 28134286 PMCID: PMC5278509 DOI: 10.1038/srep41555
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study profile.
RRT = renal dialysis treatment; OLT = orthotopic liver transplantation.
Donor characteristic with or without post-OLT AKI.
| Parameters (n = 4482) | Non-AKI | AKI | P value | Missing value |
|---|---|---|---|---|
| Age (years) | 37.92 (22.63, 47.63) | 39 (24, 47.17) | 0.597 | 679 |
| Sex (male) | 3140 (81.16) | 155 (81.58) | 0.885 | 423 |
| Blood type | 0.928 | 388 | ||
| O | 1535 (39.32) | 79 (41.58) | ||
| A | 1099 (28.15) | 52 (27.37) | ||
| B | 994 (25.46) | 47 (24.74) | ||
| AB | 276 (7.07) | 12 (6.32) | ||
| China classification of DCD | 0.005 | 60 | ||
| Grade I | 536 (12.67) | 19 (9.95) | ||
| Grade II | 1822 (43.06) | 105 (54.97) | ||
| Grade III | 1873 (44.27) | 67 (35.08) | ||
| Cause of donor death | 0.007 | 1765 | ||
| Trauma | 1452 (56.61) | 86 (56.58) | ||
| Cerebrovascular accident | 1452 (56.61) | 86 (56.58) | ||
| Brain tumor | 134 (5.22) | 16 (10.53) | ||
| Hypoxic brain injury | 73 (2.85) | 5 (3.29) | ||
| Others | 255 (9.94) | 4 (2.63) | ||
| Toxicosis | 7 (0.27) | 0 (0) | ||
| Preoperative data of donor | ||||
| Past medical history | ||||
| Diabetes | 8 (0.19) | 0 (0) | — | |
| Hypertension | 121 (2.82) | 8 (4.12) | 0.289 | |
| Respiratory diseases | 4 (0.09) | 1 (0.52) | 0.199 | |
| Cardiovascular diseases | 11 (0.26) | 0 (0) | — | |
| Others | 69 (1.61) | 9 (4.64) | 0.002 | |
| None | 1709 (39.86) | 91 (46.91) | 0.050 | |
| Donor blood examination | ||||
| Na+ | 144 (138, 155) | 153.15 (138.9, 164) | 0.008 | 2810 |
| K+ | 3.99 (3.57, 4.5) | 4 (3.5, 4.6) | 0.465 | 3040 |
| BUN | 6.83 (4.68, 10.83) | 9.78 (5.41, 15.14) | <0.001 | 2655 |
| Albumin | 33.38 (28, 39) | 30.6 (27.3, 36.6) | 0.003 | 2652 |
| ALP | 87 (58.5, 122) | 85 (61.5, 116.9) | 0.825 | 3122 |
| Blood sugar | 7.65 (5.5, 10.9) | 8.5 (6.8, 11.69) | 0.039 | 3428 |
| Total bilirubin (μmol/L) | 14.5 (9.3, 23) | 14.65 (9.6, 22.9) | 0.782 | 2601 |
| sCr (μmol/L) | 79 (53.9, 121.95) | 103.5 (64.85, 206.5) | <0.001 | 2598 |
| GGT | 37 (19, 79) | 42 (14, 87) | 0.607 | 3005 |
| AST (U/L) | 50.4 (30, 91.2) | 61 (37, 113) | 0.011 | 2641 |
| ALT (U/L) | 36 (21, 76) | 41.25 (23.5, 75) | 0.330 | 2624 |
Demographic and preoperative clinical data of recipients with or without post-OLT AKI.
| Characteristics | Non-AKI (n = 4288) | AKI (n = 194) | P value |
|---|---|---|---|
| Age, years (mean) | 48.4 (40.4, 55.8) | 50.5 (41.9, 58.7) | 0.056 |
| Male sex, n (%) | 3444 (80.32) | 147 (75.77) | 0.121 |
| BMI, (mean, SD) | 22.77 (20.76, 24.69) | 22.33 (20.76, 24.49) | 0.072 |
| Preoperative data, n (%) | |||
| Blood type compatibility, n (%) | 3757 (87.62) | 175 (90.21) | 0.004 |
| Hepatocarcinoma-related disease, n (%) | <0.001 | ||
| HCC | 1630 (38.01) | 54 (27.84) | |
| Benign disease | 1630 (38.01) | 68 (35.05) | |
| Others | 1028 (23.97) | 72 (37.11) | |
| Hepatitis B, n (%) | 2723 (63.5) | 130 (67.01) | 0.321 |
| Cirrhosis, n (%) | 3411 (79.55) | 138 (71.13) | 0.005 |
| Hepatic failure, n (%) | 311 (7.25) | 35 (18.04) | <0.001 |
| Preoperative dialysis, n (%) | 312 (7.28) | 20 (10.31) | 0.115 |
| Total bilirubin (μmol/L), (mean L b) | 102 (27.8, 356) | 143 (29, 450) | 0.461 |
| Serum creatinine (μmol/L), (mean L c) | 74.6 (56.2, 110) | 85 (64, 136) | 0.003 |
| INR, (mean score) | 1.58 (1.2, 2.62) | 1.63 (1.25, 2.5) | 0.485 |
| MELD score, (mean score) | 20 (12, 33) | 23 (13, 35) | 0.109 |
| Child-Pugh grade, (mean C-P) | 10 (8, 12) | 10 (8, 12) | 0.204 |
| Albumin (g/dL), (mean min) | 3.34 (2.91, 3.8) | 3.38 (3, 3.89) | 0.571 |
Intraoperative clinic data (mean range) of recipients with or without post-OLT AKI.
| Parameters | Non-AKI (n = 4288) | AKI (n = 194) | P value |
|---|---|---|---|
| Duration of surgery (h) | 7.25 (6.07, 8.53) | 7.28 (5.67, 8.92) | 0.916 |
| Cold ischemia time (h) | 6.17 (4.5, 8.63) | 7 (5, 10.53) | 0.043 |
| Warm ischemia time (min) | 5 (2, 8) | 5 (3.25, 14) | <0.001 |
| Intraoperative blood loss (mL) | 1600 (800, 3000) | 2500 (1500, 6000) | <0.001 |
| Whole blood (mL) | 1200 (800, 2400) | 1260 (800, 2000) | 0.627 |
| Red blood cells (mL) | 1600 (800, 2400) | 2000 (1100, 4000) | <0.001 |
| Cell saver (mL) | 2800 (1600, 4000) | 4600 (800, 6400) | 0.701 |
| Autologous blood cell transfusion (mL) | 800 (500, 1500) | 1225 (600, 2950) | 0.015 |
| Fresh frozen plasma (mL) | 1450 (800, 2060) | 1850 (1080, 2810) | <0.001 |
| Platelet (units) | 2 (1, 10) | 2 (1, 9) | 0.764 |
| Total volume of intravenous infusion (mL) | 5500 (3500, 7652) | 6611.5 (4975, 9990) | <0.001 |
| Noradrenaline (%) | 1458 (34) | 107 (55.2) | <0.001 |
| Dobutamine (%) | 772 (18) | 72 (37.1) | <0.001 |
Postoperative clinical data of recipients with or without post-OLT AKI.
| Factors | Non-AKI (n = 4288) (%) | AKI (n = 194) (%) | P value |
|---|---|---|---|
| Postoperative complications | |||
| Intraperitoneal hemorrhage | 194 (4.52) | 64 (32.99) | <0.001 |
| Biliary complications | 198 (4.62) | 10 (5.15) | 0.728 |
| Vascular complications | 152 (3.54) | 17 (8.76) | <0.001 |
| Abnormal graft function | 71 (1.66) | 55 (28.35) | <0.001 |
| Postoperative infection | 677 (15.79) | 87 (44.85) | <.001 |
| Diabetes | 537 (12.52) | 42 (21.65) | <0.001 |
| Hypertension | 144 (3.36) | 12 (6.19) | 0.036 |
| New-onset diabetes | 430 (10.03) | 32 (16.49) | 0.004 |
| New-onset hypertension | 94 (2.19) | 6 (3.09) | 0.406 |
| Cytomegalovirus infection | 51 (1.19) | 2 (1.03) | 0.847 |
| Pleural effusion | 989 (23.06) | 95 (48.97) | <0.001 |
| Pneumonedema | 40 (0.93) | 20 (10.31) | <0.001 |
| Intra-abdominal abscess | 481 (11.22) | 64 (32.99) | <0.001 |
| Initial induction of CNI | |||
| Tacrolimus | 2680 (62.51) | 146 (75.02) | 0.015 |
| Cyclosporine | 391 (9.11) | 25 (13.04) | 0.027 |
| Average CNI trough level (ng/ml) | |||
| Tacrolimus | 9.2 (8.8, 9.6) | 10.3 (9.8, 10.7) | 0.008 |
| Cyclosporine | 178.5 (172, 185) | 174.1 (162, 181) | 0.324 |
| Overexposure to CNI | 527 (12.30) | 93 (48.14) | <0.001 |
| MMF use | 3044 (71.08) | 81 (42.10) | <0.001 |
| Dobutamine (days) | 1.2 (0.0, 2.4) | 3.5 (0.8, 6.2) | <0.001 |
| Dopamine (days) | 3.2 (1.1, 5.3) | 5.4 (3.5, 7.3) | <0.001 |
| Length of hospital stay (days) | 25 (18,35) | 16 (6,34.5) | <0.001 |
| Follow-up duration (month) | 3.82 (0.92, 10.66) | 0.72 (0.2, 3.88) | <0.001 |
Figure 2Kaplan-Meier Curves for (A) the recipients and (B) the grafts.
Multivariate analysis of the risk factors of post-OLT AKI.
| Factors | OR | 95% CI | P value | ||
|---|---|---|---|---|---|
| Cold ischemia time | <7 h | 1 | — | — | |
| >7 h | 1.061 | 1.032 | 1.09 | <0.001 | |
| Warm ischemia time | <10 min | 1 | — | — | |
| >10 min | 1.028 | 1.011 | 1.046 | 0.001 | |
| Blood loss | <2500 mL | 1 | — | — | |
| >2500 mL | 1.23 | 1.001 | 1.451 | <0.001 | |
| SCr | <354 μmol/L | 1 | — | — | |
| >354 μmol/L | 1.352 | 1.181 | 1.763 | <0.001 | |
| Treatment with dopamine | <6 days | 1 | — | — | |
| >6 days | 1.854 | 1.425 | 2.281 | <0.001 | |
| Overexposure to CNI | No | 1 | — | — | |
| Yes | 2.841 | 1.762 | 5.360 | <0.001 | |
| Combined use of MMF | Yes | 1 | — | — | |
| No | 2.184 | 1.338 | 6.89 | 0.023 | |
Figure 3Receiver operating characteristic (AUC) cure of the risk factors for the occurrence post-OLT AKI.